Search
for
Sort by
Research 631–660 of 674
- Exosome-based Therapies for Androgenetic Alopecia: Mechanisms, MicroRNAs, and Clinical Prospects
- The Mechanism and Research Progress of Skin Microbiota in Pathogenesis of Acne
- Research Progress of Extracellular Vesicles-Loaded Microneedle Technology
- An <i>mTurq2-Col4a1</i> mouse model allows for live visualization of mammalian basement membrane development
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Opposing impacts on healthspan and longevity by limiting dietary selenium in telomere dysfunctional mice
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Under Development JAK Inhibitors for Dermatologic Diseases
- Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
- Baricitinib for the Treatment of Alopecia Areata
- Glycerophospholipid Analysis of Eastern Red Bat (Lasiurus Borealis) Hair by Electrospray Ionization Tandem Mass Spectrometry
- Renal tubular dysfunction presenting as recurrent hypokalemic periodic quadriparesis in systemic lupus erythematosus
- Friend or foe: A systematic review of dupilumab and alopecia areata
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Dietary supplementation with L-glutamine enhances immunity and reduces heat stress in Hanwoo steers under heat stress conditions
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review